Life Length® to participate in Frailomic, largest funded study on frailty in the European Union; partner with World Health Organization

Life Length<span class="superindice">®</span> to participate in Frailomic, largest funded study on frailty in the European Union; partner with World Health Organization

31 Ene Life Length® to participate in Frailomic, largest funded study on frailty in the European Union; partner with World Health Organization

Life Length®, has announced that it has been accepted as a partner in the Frailomic Study which has been granted €12 million in financial support under the FP7 program funded by the EU. Life Length has been assigned a budget of €830,000 for its portion of the work which will consist of telomere measuring using its proprietary Telomere Analysis Technology (TAT). Frailomic is a project with 20 European leading academic institutions and companies that will carry out the five-year study to establish biomarkers to determine risk of frailty. Other participants in the study, from more eight countries include the World Health Organization, Universitat De Valencia, University Of Bedfordshire, Friedrich-Schiller-Universitaet Jena among others. With 75,000 participants from eight cohorts this study will be important to validate the questions of frailty. Frailty is considered highly prevalent in old age and to confer high risk for falls, disability, hospitalization, and mortality. Frailty has been considered synonymous with disability, comorbidity, and other characteristics, but it is recognized that it may have a biologic basis and be a distinct clinical syndrome. A standardized definition has not yet been established. Recent documents stress the necessity of testing the clinical utility (in terms of risk prediction, diagnosis validity and prognostic significance) of the existing definition of frailty by using combinations of clinical criteria (current definition) and lab Biomarkers (BMs). A wellbalanced consortium distributed over the individual tasks in the respective work packages will carry it out, with a strong participation of SMEs. In summary, the Frailomic Study is original, relevant, pertinent, feasible and will overcome the usual research bottlenecks on biomarkers. Stephen Matlin, Life Length, CEO noted, “Telomere Analysis Technology (TAT) is already considered by many as a crucial biomarker for the detection of the risk of age-related diseases. Life Length’s participation in this study stresses the importance of using this biomarker as a tool to understand aging and maintaining health. Aging is already becoming one of the crucial policy and health issues in the 21st century.”

No Comments

Post A Comment